In December 2014, the tascFv bispecific T-cell engager (BiTE) blinatumomab, directed against CD19 and CD3 to retarget T lymphocytes against CD19+ cells, was approved by the US Food and Drug Administration under the accelerated approval program for the treatment of acute lymphoblastic leukemia (27). Here, CD19 is linked to acute lymphoblastic leukemia.